DeHoff Kate sold $57K of JOBY

Joby Aviation (JOBY) and Archer Aviation (ACHR) face cash flow pressures and FAA certification delays. Both companies are pursuing defense contracts for early revenue. Joby has a $163M Air Force contract and acquired Resonant Sciences for $500M. Archer has a $142M Air Force contract and a deal with Anduril. Defense revenue is crucial for their financial stability.

Joby Aviation (JOBY) shares fell 49% over six months to $4.65. Blade, a subsidiary, drove Q2 revenue to $38.6M, leading to raised full-year guidance of $115M-$125M. Joby plans to acquire Resonant Sciences for $500M, with Q3 results on November 4 to update cash burn and aircraft progress. Joby reported a $197M adjusted EBITDA loss in Q2.

Joby Aviation aims to be a transportation-as-a-service company with its eVTOL aircraft, making progress with FAA-compliant and autonomous technology. Viking Therapeutics is developing obesity drug VK2735, showing promising weight loss data in trials. Both companies are high-risk, high-reward investments.

Joby Aviation (JOBY) reported a larger-than-expected Q2 loss of $0.25 per share, raising concerns about its financial resources. Barclays downgraded JOBY to 'Underweight', questioning its market potential and production capacity. ASTS, CIFR, and JOBY stocks have fallen 23-62% this year. Retail sentiment remains bullish despite the downturn.

Joby Aviation (JOBY) stock fell 68.4% in the year to October 12, 2026, despite the S&P 500 gaining 20.5%. Key events included a Goldman Sachs Sell rating, broader market adjustments, and a $116.9M damages ruling. Joby's Q2 2026 revenue was $39M, with a net loss of $245M. The company has $2.3B in cash and plans to spend $385M-$415M in the second half of 2026.

Joby Aviation (JOBY) shares dropped 8% to a 52-week low of $5.3, down 65% over the past year. Despite reporting Q2 2026 revenue of $38.6M and a $500M acquisition, investor concerns persist. Analysts have mixed ratings, with targets at $18 (Buy) and Neutral.